SAN DIEGO, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus” or the “Company”) (Nasdaq:APRI) (www.apricusbio.com), today announced that Belgium’s Ministry of Social Affairs, Public Health and Environment has granted national phase approval to Vitaros®, indicated for the treatment of patients with erectile dysfunction (“ED”). The Company has now received a total of eight national phase approvals for Vitaros®, including Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom (“UK”) following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”), for the commercialization of Vitaros® in several European countries, including Belgium.
Help employers find you! Check out all the jobs and post your resume.
